Drug intelligence / Profile preview

EC-207

Development stage: Preclinical
Lead developer: Eclipse Life Sciences
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

EC-207 is a preclinical-stage topical ophthalmic drug candidate being developed by Eclipse Life Sciences for the treatment of inflammatory dry eye disease. It is characterized as a CaM-I (Calmodulin inhibitor) that possesses dual anti-inflammatory and anti-fibrotic properties. Formulated as a topical eyedrop, EC-207 is designed to address the underlying ocular surface inflammation and the potential for fibrotic tissue remodeling associated with chronic dry eye conditions. By targeting Calmodulin-mediated pathways, the agent aims to provide a therapeutic alternative to existing anti-inflammatory treatments that may not adequately address the fibrotic components of the disease.

Other names: Topical CaM-I

Targets

CaM (Calmodulin)

Beyond the preview

Go deeper on EC-207.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EC-207.

Explore the full profile